Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective
Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi...
| Autor principal: | |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/85738 |
| Aporte de: |
| id |
I19-R120-10915-85738 |
|---|---|
| record_format |
dspace |
| institution |
Universidad Nacional de La Plata |
| institution_str |
I-19 |
| repository_str |
R-120 |
| collection |
SEDICI (UNLP) |
| language |
Inglés |
| topic |
Ciencias Exactas Designed multiple ligands Drug design Drug repositioning Drug resistance Gene profile Lock and key paradigm Multi-target agents |
| spellingShingle |
Ciencias Exactas Designed multiple ligands Drug design Drug repositioning Drug resistance Gene profile Lock and key paradigm Multi-target agents Talevi, Alan Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| topic_facet |
Ciencias Exactas Designed multiple ligands Drug design Drug repositioning Drug resistance Gene profile Lock and key paradigm Multi-target agents |
| description |
Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed. |
| format |
Articulo Articulo |
| author |
Talevi, Alan |
| author_facet |
Talevi, Alan |
| author_sort |
Talevi, Alan |
| title |
Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| title_short |
Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| title_full |
Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| title_fullStr |
Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| title_full_unstemmed |
Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| title_sort |
multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective |
| publishDate |
2015 |
| url |
http://sedici.unlp.edu.ar/handle/10915/85738 |
| work_keys_str_mv |
AT talevialan multitargetpharmacologypossibilitiesandlimitationsoftheskeletonkeyapproachfromamedicinalchemistperspective |
| bdutipo_str |
Repositorios |
| _version_ |
1764820488826126339 |